BioCentury
ARTICLE | Clinical News

X-82: Phase I/II start

September 24, 2012 7:00 AM UTC

Next month, Xcovery will begin the open-label, dose-escalation, U.S. Phase I/II X82-OPH-102 trial to evaluate oral X-82 in up to 20 patients with wet AMD. Lucentis ranibizumab rescue treatment will b...